Biotech Stock Mailbag: Keryx, Amarin, ImmunoCellular

Written by: Adam Feuerstein 06/08/12 - 9:33 AM EDT

Tickers in this article: IMGN IMUC KERX AMRN

Follow TheStreet on Twitter and become a fan on Facebook.

More Headlines

Biotech Stock Mailbag: Amarin, MannKind, Palatin
Cubist, Optimer, Trius: Antibiotic Deal Making On Tap
It's About NCE) ">Why Keryx is Lagging But Acadia is Zooming ( It's About NCE)
2013 FDA Drug Approval Calendar
Biotech Stock Mailbag: Vical, Sangamo, Spectrum Pharma